Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Status Not yet recruiting

Clinical Trial Summary

A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)

Clinical Trial Description

Efficacy assessments will be made according to the revised response criteria for malignant lymphoma based on the guidelines of the Lugano Classification (as reported by Cheson B et al. 2014) and will be based on investigator assessment Efficacy will be evaluated in terms of CR rate, ORR, PFS, EFS, OS. The safety and tolerability of study treatment will be evaluated by means of AE reports (nature, severity, frequency, causality), performance status, physical examinations, ECG and laboratory safety evaluations. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05006664
Study type	Interventional
Source	Czech Lymphoma Study Group
Contact	Marek Trnený, prof. MD
Phone	+420 224 962 527
Email	trneny@cesnet.cz
Status	Not yet recruiting
Phase	Phase 2
Start date	October 2021
Completion date	October 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03547700` - Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)	Phase 1/Phase 2
Completed	`NCT02788916` - A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas	N/A
Completed	`NCT02567656` - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma	Phase 1
Completed	`NCT01142674` - T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
Withdrawn	`NCT03355768` - Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL	Phase 3
Terminated	`NCT00514722` - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies	N/A
Completed	`NCT01679860` - Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma	Phase 2
Recruiting	`NCT06254495` - A Safety Study of SGN-35C in Adults With Advanced Cancers	Phase 1
Completed	`NCT05137847` - A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Terminated	`NCT03601819` - Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders	Phase 1
Completed	`NCT03049449` - T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas	Phase 1
Completed	`NCT00211185` - A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma	Phase 2
Not yet recruiting	`NCT03051581` - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma	N/A
Not yet recruiting	`NCT03051568` - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma	N/A
Completed	`NCT00646854` - Alemtuzumab and CHOP in T-cell Lymphoma	Phase 3
Terminated	`NCT02535247` - Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT02364466` - Cohort of Peripheral T Cell Lymphoma	N/A
Recruiting	`NCT02404571` - GDP in Frontline Chemotherapy for Patients With PTCL-NOS	Phase 2
Completed	`NCT03742921` - ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
Completed	`NCT02181218` - Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas	Phase 1